Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center

Purpose: Pediatric low-grade gliomas (PLGG) have an excellent overall survival, but frequently need non-surgical therapy at diagnosis or after progression when located in unresectable sites such as the optic pathway. Chemotherapy side effects have led to the need for better-tolerated regimens with a...

Full description

Bibliographic Details
Main Authors: Margarida Simão-Rafael, Ofelia Cruz, Sara Perez-Jaume, Vicente Santa-María Lopez, Cinzia Lavarino, Hector Salvador, Jordi Muchart López, Jose Hinojosa, Mariona Suñol, Andrés Morales La Madrid
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:EJC Paediatric Oncology
Subjects:
Bevacizumab
Pediatric low-grade glioma
Pilocytic astrocytoma
NF1
Biological therapy
Optic pathway glioma
Online Access:http://www.sciencedirect.com/science/article/pii/S2772610X23001137

Internet

http://www.sciencedirect.com/science/article/pii/S2772610X23001137

Similar Items